“…High levels of PLK4 correlate with tumor growth, aggressive progression and treatment resistance representing a poor-prognostic marker. This accounts for a variety of malignancies including several epithelial cancer types (reviewed by [ 11 , 89 ]) such as breast cancer [ 196 , 197 , 198 , 199 ], lung cancer [ 200 , 201 ], prostate cancer [ 202 ], and gastric cancer [ 203 , 204 ], but also for neuroblastoma [ 205 ], glioblastoma [ 206 ], and acute leukemia [ 207 , 208 ]. In skin epidermis, overexpression of PLK4 leads to hyperplasia [ 209 ] and promotes—in association with p53 deficiency—tumorigenesis causing hyperproliferation and abnormal differentiation of basal keratinocytes and melanocytes [ 209 , 210 ].…”